Altimmune, Inc. · NASDAQ:ALT
Altimmune — Technical Presentation (November 2026)
17 slides from Altimmune's technical presentation, Nov 9, 2026
Slide 1: Efficacy and Safety of Pemvidutide in Adults with Alcohol Use Disorder: RECLAIM
Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo- Controlled Trial Henry R. Kranzler1, Shaheen Tomah2, W. Kyle Simmons3, Stephanie S. O’Malley4, Joseph P. Schacht5, Xiaoxi Li2, Christophe
Slide 2: Disclosures
Disclosures Dr. Kranzler’s Disclosures: Dr. Kranzler serves on advisory boards for Altimmune, Inc. and Clearmind Medicine; consults for Altimmune, Inc., Eli Lilly and Company, Sobrera Pharmaceuticals, Ribocure and Boehringer Ingelheim; and receives research support from Alkermes, Altimmune, and Eli
Slide 3: Alcohol Use Disorder Causes Severe Clinical Complications with Substantial Gaps in Care
INTRODUCTION Alcohol Use Disorder (AUD) Causes Severe Clinical Complications with Substantial Gaps in Current Care Epidemiological Burden Healthcare Burden Clinical Burden 57.9M Engage in binge ~2M Adult hospitalizations ~178,000 Deaths annually drinking monthly annually due to excessive alcohol use
Slide 4: Pemvidutide is a Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist
INTRODUCTION Pemvidutide is a Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist COOH Glucagon specificity EuPort Domain (CH2)n Provides direct liver effects, including liver Allows for weekly dosing and fat reduction, leading to reductions in may contribute to tolerabilitya inflammation and fibrosis
Slide 5: RECLAIM Phase 2 AUD Trial Design
METHODS RECLAIM Phase 2 AUD Trial Design A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of pemvidutide in AUD (NCT06987513) Week 24 Endpoints Week 0 Week 24 Primary endpoint Adult Patient Population 4 weeks 4 weeks 16 weeks • Heavy drink
Slide 6: High Overall Retention (91%) with Similar Treatment Discontinuation Across Groups
RESULTS High Overall Retention (91%) with Similar Treatment Discontinuation Across Groups 194 assessed for eligibility 94 screen failures 100 randomized Placebo (N=50) Pemvidutide 2.4 mg (N=50) 11 discontinued treatmenta 10 discontinued treatmentb 39 (78%) completed treatment 40 (80%) completed trea
Slide 7: Demographic and Baseline Clinical Characteristics Similar Across Groups
RESULTS Demographic and Baseline Clinical Characteristics Similar Across Groups Characteristic Placebo (N=50) Pemvidutide 2.4 mg (N=50) Age, years (SD) 50.0 (10.0) 50.8 (11.9) Female sex, n (%) 26 (52) 26 (52) Body weight, kg (SD) 96.0 (21.4) 92.0 (19.1) BMI, kg/m2 (SD) 32.5 (6.6) 32.3 (5.8) AUD by
Slide 8: Significantly Greater Reduction in Heavy Drinking Days/Week than Placebo
RESULTS Pemvidutide Achieved Significantly Greater Reduction in Heavy Drinking Days/Week than Placebo (Primary Endpoint) Heavy Drinking Days (HDDs)/Week 0 LSM Change from Baseline (HDD/Week ± SE) *P = 0.0014 • Pemvidutide met the trial’s primary endpoint at -1 week 24 (reduction in HDDs/week) -2 o T
Slide 9: Maintained Reduction in HDDs/Week in Sensitivity Analysis
RESULTS Pemvidutide Maintained Reduction in HDDs/Week (Primary Endpoint) in Sensitivity Analysis Sensitivity Analysisa for Heavy Drinking Days (HDDs)/Week 0 LSM Change from Baseline (HDD/week ± SE) P = 0.008 -1 • The treatment effect on the primary endpoint at week 24 (reduction in HDDs/week) remain
Slide 10: Higher Rates of ≥2-level WHO-RDL Reduction and Zero HDDs
RESULTS Pemvidutide Achieved Higher Rates of a ≥2-level WHO- RDL Reduction and Zero HDDs (FDA Registrational Endpoints) ≥2-level World Health Organization Zero Heavy Drinking Days Risk Drinking Level (WHO-RDL) 100% 100% *P = 0.0049 P = 0.0066 Percentage of Patients (%) 80% 80% Percentage of Patients
Slide 11: Reduction in Serum PEth Levels
RESULTS Pemvidutide Showed a Reduction in Serum PEth Levels (Sensitive and Specific Biomarker of Alcohol Consumption) Serum Phosphatidylethanol (PEth) 100 P <0.0001 LSM Change from Baseline (ng/mL ± SE) 22.0 50 0 • Self-reported drinking outcomes were corroborated by reductions in objective -50 PEth
Slide 12: Increase in Percent Days Abstinent
RESULTS Pemvidutide Showed an Increase in Percent Days Abstinent Percent Days Abstinent (PDA) Drinks Per Drinking Daya (DDD) LSM Change from Baseline (Average DDD ± SE) 50 0 LSM Change from Baseline (% of Days ± SE) P = 0.0075 38.9% P = 0.203 -1 40 -2 30 20.5% -3 -3.8 20 -4 10 -5 Placebo (n=50) Plac
Slide 13: Progressive Decrease in Body Weight and Reduced FIB-4 Scores
RESULTS Pemvidutide Showed Progressive Decrease in Body Weight and Reduced FIB-4 Scores Change in FIB-4 Score At Week 24 Among Percent Change in Body Weight Patients with Baseline FIB-4 ≥1.3a (n=25) 2 P <0.0001 P = 0.0301 LSM Percent Change from Baseline (% ± SE) 0.4% 0.4 0.2 LSM Change from Baselin
Slide 14: Adverse Events Were Predominantly Mild or Moderate
RESULTS Adverse Events Were Predominantly Mild or Moderate Event, n (%) Placebo (N=50) Pemvidutide 2.4 mg (N=50) Serious adverse events 1 (2.0)a 2 (4.0)b Serious adverse events related to trial drug 0 (0.0) 1 (2.0) Severe adverse events 3 (6.0) 6 (12.0) Severe adverse events related to trial drug 0
Slide 15: Summary and Future Directions
Summary ▪ The RECLAIM trial met its primary endpoint, with pemvidutide demonstrating a significantly greater reduction in HDDs/week than placebo among patients with moderate-to-severe AUD ▪ Patients treated with pemvidutide showed consistent improvements in other measures of self- reported alcohol c
Slide 16: Acknowledgements
Acknowledgements • This study was funded by Altimmune, Inc. • Patients & Clinical Trial Team o Patients for their important contributions to this trial o Clinical investigators and the Altimmune clinical trial team who contributed to the conduct of the trial • Medical Communications Support o Boston
Slide 17: Thank you! Questions?
Thank you! Questions? AASLD